Vaxil Bio Therapeutics Ltd.http://www.vaxilbio.com
Sub-category: Antibody, Immunotherapy & Vaccines
Vaxil BioTherapeutics is a clinical stage biotechnology company developing novel, therapeutic vaccines for cancer and infectious diseases. Vaxil’s lead therapeutic vaccine, ImMucin is currently being evaluated in a Phase I/II clinical trial in multiple myeloma patients at Hadassah Medical Center, Jerusalem. Vaxil is also developing a vaccine against mycobacterium Tuberculosis (MTb) currently in preclinical animal studies. These vaccines were identified using a proprietary technology called VaxHit which uses the Signal Peptide (SP) domains of the target as the core antigen. Vaxil was founded in late 2006 by an experienced management team supported by leading scientists and clinicians from Israel Europe and the USA.
Vaxil's VaxHit technology combines proprietary algorithms which enable in-silico identification of unique ~15-40mer SP antigenic sequences (domains) and their subsequent use as vaccines. These novel candidates offer several advantages over current alternatives:
A. Although, Vaxil's vaccines have the considerable advantage of being relatively short sequences, they also induce a broader, stronger and antigen specific Th1 type immunity via promiscuous activation of multiple T-cell clones both CD4+ and CD8+ T-cells and the secretion of key cytokines like IFN-gamma and IL-2.
B. Vaxil's vaccines induce an efficient response in the majority of the population due to their ability to bind multiple HMC alleles. This is critical as every individual express different set of MHC alleles. Unlike other peptide vaccines, Vaxil's vaccines do not require patients selected according to their HLA repertoire.
C. Vaxil's vaccines are able to efficiently overcome difficulties posed by immune escape mechanisms, mainly TAP deficiency, mediated by cancer cells and intracellular pathogens. To the best of our knowledge, these are the only vaccines which currently offer this crucial property.
Utilizing VaxHit, Vaxil has to date identified several vaccine candidates, including, the company's lead product ImMucin which is an anti-MUC1 vaccine. MUC1 is one of the most promising target antigens (TAA) known today which is expressed by over 90% of the common solid epithelial tumors and main non-solid tumors. Unlike other MUC1 clinical programmes which targets the well known Tandem Repeat Array (TRA) domain on MUC1, ImMucin is directed against a less explored SP domain with unique antigenic and immunodominant properties. In preclinical studies, ImMucin manifested superior activity vs. a selection of other MUC1-TRA derived peptide vaccines. ImMucin It is currently being evaluated in a Phase I/II clinical trial in multiple myeloma patients which is being carried out at Hadassah Medical Center, Jerusalem, Israel.
VaxHit also enables the identification of vaccines against selected intracellular pathogens. Vaxil is developing a Tuberculosis vaccine – MTbuVax. This is a multi epitope subunit vaccine with epitopes derived from the SP domains of known and novel MTb antigens. It has been selected by its applicability to all populations (HLA-Wise) worldwide MTbuVax has already manifested superior immunity in a large number of blood samples derived from na?ve individual and patient with active TB comparing to known peptide vaccines from the same antigens. MTbuVax is currently in preclinical studies.
|Lior Carmon, CEO|
|Building 13A, 13 Einstein St. Weizmann Science Park, Nes-Ziona, Israel 74036|
To update your company data, click here.